Biogen inks $357M option deal for TMS' stroke drug

Biogen believes TMS-007 could complement another stroke asset, acquired last year, which is scheduled to enter a phase 3 trial by the end of the month. (Biogen)

Biogen signed a deal for an exclusive chance to acquire TMS’ treatment for restoring blood flow after acute ischemic stroke, which is currently being evaluated in a placebo-controlled phase 2 study in Japan.

The agreement’s $4 million upfront payment could grow by an additional $18 million if Biogen decides to exercise its option, and possibly balloon by $335 million more if the drug hits its development, commercialization and sales targets.

TMS’ plasminogen activator, TMS-007, uses a novel mechanism of action to break down blood clots, and is thought to inhibit inflammation at the clotting site, according to the Tokyo-based company, which believes the drug could have an extended treatment window compared to other thrombolytic agents.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“TMS-007 complements our broader efforts in stroke, including our phase 3 ready asset BIIB093 (intravenous glibenclamide), which targets prevention and treatment of edema in large hemispheric infarction, one of the most severe types of stroke,” Biogen’s executive VP of R&D, Michael Ehlers, said in a statement. The option deal also includes the small molecule’s backup compounds.

“By growing our acute neurology portfolio, we aim to make new advances in a disease that in the past decades has seen limited therapeutic innovation.”

In a phase 1 study, TMS-007 demonstrated an acceptable safety profile, according to Biogen, and has also reduced area of dead tissue resulting from failure of blood supply in rodent and primate embolic and thrombotic stroke models.

The ongoing double-blind phase 2 study, launched in February, is designed to investigate safety and efficacy of a single IV administration in 60 to 90 patients up to 12 hours after onset of acute ischemic stroke.

RELATED: Biogen buys Remedy’s phase 3 stroke drug for $120M

Last year, Biogen paid $120 million upfront for BIIB093, then known as Cirara, from Remedy Pharmaceuticals. Cirara had also received an FDA Fast Track designation.

Biogen plans to launch a new phase 3 trial of BIIB093 by the end of this month, estimating an enrollment of 680 participants and scheduled to be completed by September 2020. The study will measure improvement in function after 90 days in patients with acute ischemic stroke.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.